APO Research
Talk to an analyst

APO RESEARCH · REPORT

Immuno-Oncology Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Immuno-Oncology Service Market Outlook and Growth Opportunities 2026

5 June 2026193 pages

Choose your research edition.

Industry ResearchImmuno-Oncology Service Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-Oncology Service Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Immuno-Oncology Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-Oncology Service Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-Oncology Service Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Immuno-Oncology Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immuno-Oncology Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Immuno-Oncology Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Immuno-Oncology Service market include Crown Bioscience, Bio-Techne, Abcam, WuXi AppTec, Shanghai ChemPartner, George Clinical, Laboratory Corporation of America® Holdings, Medpace and Genscript, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Immuno-Oncology Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immuno-Oncology Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immuno-Oncology Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Immuno-Oncology Service market.

Immuno-Oncology Service Segment by Company

Crown Bioscience

Bio-Techne

Abcam

WuXi AppTec

Shanghai ChemPartner

George Clinical

Laboratory Corporation of America® Holdings

Medpace

Genscript

Shanghai Novamab Biopharmaceuticals

LIDE

TransCure bioServices

Immuno-Oncology Service Segment by Type

Basic Research

Clinical Research

Immuno-Oncology Service Segment by Application

Pharmaceutical Companies

Medical Device Companies

Other

Immuno-Oncology Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Immuno-Oncology Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Immuno-Oncology Service key companies, revenue, market share, and recent developments.

3. To split the Immuno-Oncology Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Immuno-Oncology Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Immuno-Oncology Service significant trends, drivers, influence factors in global and regions.

6. To analyze Immuno-Oncology Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-Oncology Service industry.

Chapter 3: Detailed analysis of Immuno-Oncology Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Immuno-Oncology Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Immuno-Oncology Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Immuno-Oncology Service Industry Trends Table 2. Immuno-Oncology Service Industry Drivers Table 3. Immuno-Oncology Service Industry Opportunities and Challenges Table 4. Immuno-Oncology Service Industry Restraints Table 5. Global Immuno-Oncology Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Immuno-Oncology Service Revenue Share by Company (2021-2026) Table 7. Global Immuno-Oncology Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Immuno-Oncology Service Key Company Manufacturing Base & Headquarters Table 9. Global Immuno-Oncology Service Company, Product Type & Application Table 10. Global Immuno-Oncology Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Immuno-Oncology Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Basic Research Table 15. Significant Companies of Clinical Research Table 16. Global Immuno-Oncology Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Immuno-Oncology Service Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Immuno-Oncology Service Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Immuno-Oncology Service Sales Value Share by Type (2021-2026) Table 20. Global Immuno-Oncology Service Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Pharmaceutical Companies Table 22. Significant Companies of Medical Device Companies Table 23. Significant Companies of Other Table 24. Global Immuno-Oncology Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Immuno-Oncology Service Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Immuno-Oncology Service Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Immuno-Oncology Service Sales Value Share by Application (2021-2026) Table 28. Global Immuno-Oncology Service Sales Value Share by Application (2027-2032) Table 29. Global Immuno-Oncology Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Immuno-Oncology Service Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Immuno-Oncology Service Sales Value Share by Region (2021-2026) Table 32. Global Immuno-Oncology Service Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Immuno-Oncology Service Sales Value Share by Region (2027-2032) Table 34. Global Immuno-Oncology Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Immuno-Oncology Service Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Immuno-Oncology Service Sales Value Market Share by Country (2021-2026) Table 37. Global Immuno-Oncology Service Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Immuno-Oncology Service Sales Value Market Share by Country (2027-2032) Table 39. Crown Bioscience Company Information Table 40. Crown Bioscience Business Overview Table 41. Crown Bioscience Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Crown Bioscience Immuno-Oncology Service Product Portfolio Table 43. Crown Bioscience Recent Development Table 44. Bio-Techne Company Information Table 45. Bio-Techne Business Overview Table 46. Bio-Techne Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Bio-Techne Immuno-Oncology Service Product Portfolio Table 48. Bio-Techne Recent Development Table 49. Abcam Company Information Table 50. Abcam Business Overview Table 51. Abcam Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Abcam Immuno-Oncology Service Product Portfolio Table 53. Abcam Recent Development Table 54. WuXi AppTec Company Information Table 55. WuXi AppTec Business Overview Table 56. WuXi AppTec Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. WuXi AppTec Immuno-Oncology Service Product Portfolio Table 58. WuXi AppTec Recent Development Table 59. Shanghai ChemPartner Company Information Table 60. Shanghai ChemPartner Business Overview Table 61. Shanghai ChemPartner Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Shanghai ChemPartner Immuno-Oncology Service Product Portfolio Table 63. Shanghai ChemPartner Recent Development Table 64. George Clinical Company Information Table 65. George Clinical Business Overview Table 66. George Clinical Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. George Clinical Immuno-Oncology Service Product Portfolio Table 68. George Clinical Recent Development Table 69. Laboratory Corporation of America® Holdings Company Information Table 70. Laboratory Corporation of America® Holdings Business Overview Table 71. Laboratory Corporation of America® Holdings Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio Table 73. Laboratory Corporation of America® Holdings Recent Development Table 74. Medpace Company Information Table 75. Medpace Business Overview Table 76. Medpace Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Medpace Immuno-Oncology Service Product Portfolio Table 78. Medpace Recent Development Table 79. Genscript Company Information Table 80. Genscript Business Overview Table 81. Genscript Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Genscript Immuno-Oncology Service Product Portfolio Table 83. Genscript Recent Development Table 84. Shanghai Novamab Biopharmaceuticals Company Information Table 85. Shanghai Novamab Biopharmaceuticals Business Overview Table 86. Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio Table 88. Shanghai Novamab Biopharmaceuticals Recent Development Table 89. LIDE Company Information Table 90. LIDE Business Overview Table 91. LIDE Immuno-Oncology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. LIDE Immuno-Oncology Service Product Portfolio Table 93. LIDE Recent Development Table 94. TransCure bioServices Company Information Table 95. TransCure bioServices Business Overview Table 96. TransCure bioServices Immuno-Oncology Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. TransCure bioServices Immuno-Oncology Service Product Portfolio Table 98. TransCure bioServices Recent Development Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Immuno-Oncology Service Product Image Figure 2. Global Immuno-Oncology Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-Oncology Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Immuno-Oncology Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Basic Research Image Figure 8. Clinical Research Image Figure 9. Global Immuno-Oncology Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Immuno-Oncology Service Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Immuno-Oncology Service Sales Value Share by Type (2021-2032) Figure 12. Pharmaceutical Companies Image Figure 13. Medical Device Companies Image Figure 14. Other Image Figure 15. Global Immuno-Oncology Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Immuno-Oncology Service Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Immuno-Oncology Service Sales Value Share by Application (2021-2032) Figure 18. Global Immuno-Oncology Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Immuno-Oncology Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Immuno-Oncology Service Sales Value (2021-2032) & (US$ Million) Figure 21. North America Immuno-Oncology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Immuno-Oncology Service Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Immuno-Oncology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Immuno-Oncology Service Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Immuno-Oncology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Immuno-Oncology Service Sales Value (2021-2032) & (US$ Million) Figure 27. South America Immuno-Oncology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Immuno-Oncology Service Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Immuno-Oncology Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Immuno-Oncology Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Basic Research
  • Clinical Research
Applications
  • Pharmaceutical Companies
  • Medical Device Companies
  • Other
Companies covered
  • Crown Bioscience
  • Bio-Techne
  • Abcam
  • WuXi AppTec
  • Shanghai ChemPartner
  • George Clinical
  • Laboratory Corporation of America® Holdings
  • Medpace
  • Genscript
  • Shanghai Novamab Biopharmaceuticals
  • LIDE
  • TransCure bioServices

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Immuno-Oncology Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Immuno-Oncology Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Immuno-Oncology Service Market Dynamics
  1. 2.1 Immuno-Oncology Service Industry Trends
  2. 2.2 Immuno-Oncology Service Industry Drivers
  3. 2.3 Immuno-Oncology Service Industry Opportunities and Challenges
  4. 2.4 Immuno-Oncology Service Industry Restraints
3 Immuno-Oncology Service Market by Company
  1. 3.1 Global Immuno-Oncology Service Company Revenue Ranking in 2025
  2. 3.2 Global Immuno-Oncology Service Revenue by Company (2021-2026)
  3. 3.3 Global Immuno-Oncology Service Company Ranking (2024-2026)
  4. 3.4 Global Immuno-Oncology Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Immuno-Oncology Service Company Product Type and Application
  6. 3.6 Global Immuno-Oncology Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Immuno-Oncology Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Immuno-Oncology Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Immuno-Oncology Service Market by Type
  1. 4.1 Immuno-Oncology Service Type Introduction
  2. 4.1.1 Basic Research
  3. 4.1.2 Clinical Research
  4. 4.2 Global Immuno-Oncology Service Sales Value by Type
  5. 4.2.1 Global Immuno-Oncology Service Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Immuno-Oncology Service Sales Value by Type (2021-2032)
  7. 4.2.3 Global Immuno-Oncology Service Sales Value Share by Type (2021-2032)
5 Immuno-Oncology Service Market by Application
  1. 5.1 Immuno-Oncology Service Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Medical Device Companies
  4. 5.1.3 Other
  5. 5.2 Global Immuno-Oncology Service Sales Value by Application
  6. 5.2.1 Global Immuno-Oncology Service Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Immuno-Oncology Service Sales Value by Application (2021-2032)
  8. 5.2.3 Global Immuno-Oncology Service Sales Value Share by Application (2021-2032)
6 Immuno-Oncology Service Regional Value Analysis
  1. 6.1 Global Immuno-Oncology Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Immuno-Oncology Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Immuno-Oncology Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Immuno-Oncology Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Immuno-Oncology Service Sales Value (2021-2032)
  7. 6.3.2 North America Immuno-Oncology Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Immuno-Oncology Service Sales Value (2021-2032)
  10. 6.4.2 Europe Immuno-Oncology Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Immuno-Oncology Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Immuno-Oncology Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Immuno-Oncology Service Sales Value (2021-2032)
  16. 6.6.2 South America Immuno-Oncology Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Immuno-Oncology Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Immuno-Oncology Service Sales Value Share by Country, 2025 VS 2032
7 Immuno-Oncology Service Country-level Value Analysis
  1. 7.1 Global Immuno-Oncology Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Immuno-Oncology Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Immuno-Oncology Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Immuno-Oncology Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Immuno-Oncology Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Immuno-Oncology Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Immuno-Oncology Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Crown Bioscience
  2. 8.1.1 Crown Bioscience Company Information
  3. 8.1.2 Crown Bioscience Business Overview
  4. 8.1.3 Crown Bioscience Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Crown Bioscience Immuno-Oncology Service Product Portfolio
  6. 8.1.5 Crown Bioscience Recent Developments
  7. 8.2 Bio-Techne
  8. 8.2.1 Bio-Techne Company Information
  9. 8.2.2 Bio-Techne Business Overview
  10. 8.2.3 Bio-Techne Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bio-Techne Immuno-Oncology Service Product Portfolio
  12. 8.2.5 Bio-Techne Recent Developments
  13. 8.3 Abcam
  14. 8.3.1 Abcam Company Information
  15. 8.3.2 Abcam Business Overview
  16. 8.3.3 Abcam Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Abcam Immuno-Oncology Service Product Portfolio
  18. 8.3.5 Abcam Recent Developments
  19. 8.4 WuXi AppTec
  20. 8.4.1 WuXi AppTec Company Information
  21. 8.4.2 WuXi AppTec Business Overview
  22. 8.4.3 WuXi AppTec Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 WuXi AppTec Immuno-Oncology Service Product Portfolio
  24. 8.4.5 WuXi AppTec Recent Developments
  25. 8.5 Shanghai ChemPartner
  26. 8.5.1 Shanghai ChemPartner Company Information
  27. 8.5.2 Shanghai ChemPartner Business Overview
  28. 8.5.3 Shanghai ChemPartner Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shanghai ChemPartner Immuno-Oncology Service Product Portfolio
  30. 8.5.5 Shanghai ChemPartner Recent Developments
  31. 8.6 George Clinical
  32. 8.6.1 George Clinical Company Information
  33. 8.6.2 George Clinical Business Overview
  34. 8.6.3 George Clinical Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 George Clinical Immuno-Oncology Service Product Portfolio
  36. 8.6.5 George Clinical Recent Developments
  37. 8.7 Laboratory Corporation of America® Holdings
  38. 8.7.1 Laboratory Corporation of America® Holdings Company Information
  39. 8.7.2 Laboratory Corporation of America® Holdings Business Overview
  40. 8.7.3 Laboratory Corporation of America® Holdings Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Laboratory Corporation of America® Holdings Immuno-Oncology Service Product Portfolio
  42. 8.7.5 Laboratory Corporation of America® Holdings Recent Developments
  43. 8.8 Medpace
  44. 8.8.1 Medpace Company Information
  45. 8.8.2 Medpace Business Overview
  46. 8.8.3 Medpace Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Medpace Immuno-Oncology Service Product Portfolio
  48. 8.8.5 Medpace Recent Developments
  49. 8.9 Genscript
  50. 8.9.1 Genscript Company Information
  51. 8.9.2 Genscript Business Overview
  52. 8.9.3 Genscript Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genscript Immuno-Oncology Service Product Portfolio
  54. 8.9.5 Genscript Recent Developments
  55. 8.10 Shanghai Novamab Biopharmaceuticals
  56. 8.10.1 Shanghai Novamab Biopharmaceuticals Company Information
  57. 8.10.2 Shanghai Novamab Biopharmaceuticals Business Overview
  58. 8.10.3 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Shanghai Novamab Biopharmaceuticals Immuno-Oncology Service Product Portfolio
  60. 8.10.5 Shanghai Novamab Biopharmaceuticals Recent Developments
  61. 8.11 LIDE
  62. 8.11.1 LIDE Company Information
  63. 8.11.2 LIDE Business Overview
  64. 8.11.3 LIDE Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 LIDE Immuno-Oncology Service Product Portfolio
  66. 8.11.5 LIDE Recent Developments
  67. 8.12 TransCure bioServices
  68. 8.12.1 TransCure bioServices Company Information
  69. 8.12.2 TransCure bioServices Business Overview
  70. 8.12.3 TransCure bioServices Immuno-Oncology Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 TransCure bioServices Immuno-Oncology Service Product Portfolio
  72. 8.12.5 TransCure bioServices Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst